Michael P. Dillon

AF‐353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist

Joel R. Gever, Rothschild Soto, Robert Henningsen et al. · British Journal of Pharmacology · 2010 · 126 citations · Full text

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy

Ying Huang, Jeff Zhang, Zhengtian Yu et al. · Journal of Medicinal Chemistry · 2017 · 100 citations · Full text

Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild‐type and D79N α_2A‐adrenoceptor transgenic mice

Q‐M Zhu, John Lesnick, Jeffrey R. Jasper et al. · British Journal of Pharmacology · 1999 · 95 citations · Full text

Inside the Mind of a Medicinal Chemist: The Role of Human Bias in Compound Prioritization during Drug Discovery

Peter S. Kutchukian, Nadya Vasilyeva, Jordan Xu et al. · PLoS ONE · 2012 · 83 citations · Full text

Hit Identification, Organic Chemistry, Chemistry +20

Developing Core Sets for Persons Following Amputation Based on the International Classification of Functioning, Disability and Health as a Way to Specify Functioning

Friedbert Köhler, Alarcos Cieza, Gerold Stucki et al. · Prosthetics and Orthotics International · 2009 · 77 citations · Full text

Disability, Upper Extremity, Injury Prevention +21